• Home>
  • Stocks>
  • Alembic Pharmaceuticals Ltd Share Price
Alembic Pharmaceuticals Ltd share price logo

Alembic Pharmaceuticals Ltd Share Price

(APLLTD)

Small Cap

Healthcare Sector

₹879.8▲1.05%

as on 04:01PM, 29 Apr 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Alembic Pharmaceuticals Ltd Performance

  • Day's Low

    Day's High

    ₹870.7
    Day's Price Range
    ₹885.65

  • 52 Week's Low

    52 Week's High

    ₹725.2
    52-Week Price Range
    ₹1,303.9
1 Month Return-2.92 %
3 Month Return-4.19 %
1 Year Return-12.65 %
Previous Close₹870.70
Open₹870.70
Volume95.96K
Upper Circuit₹1,044.80
Lower Circuit₹696.60
Market Cap₹17,114.75Cr

Alembic Pharmaceuticals Ltd Fundamentals

P/E Ratio

28.91

PEG Ratio

722.69

Market Cap

₹17,114.75 Cr

P/B Ratio

3.93

EPS

31.33

Dividend Yield

1.12

Sector

Pharmaceuticals

ROE

14.3

Alembic Pharmaceuticals Ltd Analyst Rating

based on 11 analysts

BUY

45.45%

Buy

45.45%

Hold

9.09%

Sell

Based on 11 analysts offering long term price targets for Alembic Pharmaceuticals Ltd. An average target of ₹1054.64

Source: S&P Global Market Intelligence

Alembic Pharmaceuticals Ltd Share analysis

Alembic Pharmaceuticals Ltd price forecast by 11 analysts

Upside of21.13%

High

₹1411

Target

₹1054.64

Low

₹909

Alembic Pharmaceuticals Ltd target price ₹1054.64, a slight upside of 21.13% compared to current price of ₹879.8. According to 11 analysts rating.

Source: S&P Global Market Intelligence

Key events for Alembic Pharmaceuticals Ltd

  • Alembic Pharma Secures USFDA Approval for Carbamazepine - 17 Apr, 2025

    Alembic Pharmaceuticals has received final USFDA approval for Carbamazepine Tablets USP, 200 mg, which are therapeutically equivalent to Novartis' Tegretol. The estimated market size is $32 million for the next year.

  • Alembic Pharma Secures USFDA Approval for Injection - 01 Apr, 2025

    Alembic Pharmaceuticals has received USFDA approval for Pantoprazole Sodium for Injection, a significant addition to its portfolio, bringing total ANDA approvals to 221. The estimated market size for this product is $48 million for the year ending December 2024.

  • Alembic Partners with Amlan for Poultry Solutions - 25 Mar, 2025

    Alembic Pharmaceuticals has entered a strategic agreement with Amlan International to introduce advanced poultry health solutions in India, enhancing productivity and sustainability in the sector.

  • Alembic Pharma's API Facility Passes USFDA Inspection - 22 Mar, 2025

    Alembic Pharmaceuticals announced the successful completion of a USFDA inspection at its API-III facility in Karakhadi, Gujarat, with zero observations. This achievement reinforces the company's commitment to quality and regulatory compliance, enhancing its reputation in the global market.

Insights on Alembic Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 1.52K Cr → 1.70K Cr (in ₹), with an average increase of 3.7% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, APLLTD stock has moved up by 1.7%

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 8.96% to 9.20% in Mar 2025 quarter

  • imgPOSITIVE IMPACT

    Promoter Holding Up

    img

    Promoters have increased holdings from 69.61% to 69.67% in Mar 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 51.1% return, outperforming this stock by 63.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.0% return, outperforming this stock by 125.5%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 10.16% to 9.96% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 153.41 Cr → 138.42 Cr (in ₹), with an average decrease of 9.8% per quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 4.17% to 3.94% in Mar 2025 quarter

Alembic Pharmaceuticals Ltd Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹1,630.57Cr (-)₹1,516.98Cr (↓6.97%)₹1,561.73Cr (↑2.95%)₹1,647.98Cr (↑5.52%)₹1,692.74Cr (↑2.72%)
Net Income₹180.45Cr (-)₹178.21Cr (↓1.24%)₹134.54Cr (↓24.50%)₹153.14Cr (↑13.82%)₹137.70Cr (↓10.08%)
Net Profit Margin11.07% (-)11.75% (↑6.14%)8.61% (↓26.72%)9.29% (↑7.90%)8.13% (↓12.49%)
Value in ₹ crore
Details2021202220232024
Total Assets₹6,786.27Cr (-)₹7,225.33Cr (↑6.47%)₹6,213.56Cr (↓14.00%)₹6,529.82Cr (↑5.09%)
Total Liabilities₹1,684.46Cr (-)₹1,934.99Cr (↑14.87%)₹1,799.26Cr (↓7.01%)₹1,620.91Cr (↓9.91%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹539.75Cr (-)₹1,388.48Cr (↑157.25%)₹545.26Cr (↓60.73%)₹730.25Cr (↑33.93%)₹772.77Cr (↑5.82%)

Alembic Pharmaceuticals Ltd Index Inclusions

Nifty Smallcap 250

₹15,639.70

0.21 (▲32.55%)

S&P BSE 250 SmallCap

₹6,272.53

0.23 (▲14.55%)

Nifty MidSmallcap 400

₹18,431.30

0.21 (▲38.8%)

BSE 500

₹34,785.55

0.06 (▲19.76%)

BSE Healthcare

₹42,211.90

-0.81 (▲-343.75%)

Nifty 500

₹22,112.40

0.05 (▲10.55%)

S&P BSE 400 MidSmallCap

₹11,199.56

0.25 (▲27.99%)

BSE Small-Cap

₹48,238.69

0.09 (▲45.23%)

Alembic Pharmaceuticals Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
69.67%
0.00
Foreign Institutions
3.94%
0.00
Mutual Funds
9.2%
0.00
Retail Investors
9.96%
0.00
Others
7.24%
0.00

Alembic Pharmaceuticals Ltd Key Indicators

Details20202021202220232024
Earning Per Share (₹)42.4756.7226.517.431.33
Details20202021202220232024
Return On Equity %3225.9610.467.1514.3
Details20202021202220232024
Return On Assets %13.8316.897.215.59.43
Details20202021202220232024
Book Value Per Share (₹)170.79257.8266.47222.36245.14

Alembic Pharmaceuticals Ltd Valuation

Alembic Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (11.53x)

March 23, 2020

Today (28.91x)

April 28, 2025

Industry (53.89x)

April 28, 2025

Highest (53.41x)

January 3, 2023

LowHigh

Alembic Pharmaceuticals Ltd Earnings and Dividends

  • Alembic Pharmaceuticals Ltd Earnings Results

    Alembic Pharmaceuticals Ltd’s net profit fell -23.29% since last year same period to ₹138.42Cr in the Q3 2024-2025. On a quarterly growth basis, Alembic Pharmaceuticals Ltd has generated -9.77% fall in its net profits since last 3-months.

    Read More about Earnings Results

  • Alembic Pharmaceuticals Ltd Dividends May,2024

    In the quarter ending March 2024, Alembic Pharmaceuticals Ltd has declared dividend of ₹11 - translating a dividend yield of 1.25%.

    Read More about Dividends

Alembic Pharmaceuticals Ltd Technicals Summary

Bearish

Neutral

Bullish

Bullish

Alembic Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.

More on Technical Analysis

Alembic Pharmaceuticals Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd
BUY₹17,114.75 Cr2.84%0.55₹615 Cr₹6,228 Cr
Sanofi India Ltd
Sanofi India Ltd
BUY₹13,965.39 Cr-4.3%0.52₹413 Cr₹2,013 Cr
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
BUY₹73,078.26 Cr19.89%0.56₹3,168 Cr₹29,001 Cr
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
HOLD₹89,207.67 Cr34.27%0.64₹3,854 Cr₹19,547 Cr
Abbott India Ltd
Abbott India Ltd
BUY₹63,282.50 Cr13.1%0.53NANA
See all

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals is a leading generic pharmaceuticals manufacturer and marketer based in India. Established in 2010 as a subsidiary of Alembic Ltd., they stopped being a subsidiary in 2011 when they were allotted 133515914 equity shares of Rs 2 each to their shareholders. In 2014 Alembic Pharmaceuticals entered into a joint venture with Adwiya Mami SARL, Algeria and in 2015 an exclusive agreement was signed with Novartis. In 2016, Alembic Pharmaceuticals formed Aleor Dermaceuitical Limited in a 60:40 joint venture with Orbicular and a state-of-the-art anticancer manufacturing facility opened in Gujarat in 2017. One year later Alembic Pharmaceuticals completed the acquisition of Orit Laboratories LLC, a generic drug developer, along with real estate. In 2018 Alembic Pharmaceuticals was inspected by the US FDA and were issued with 3 observations. In 2019, they launched 9 new products in the US, and the novel Umbralicib UKONIQ was licensed by TG Therapeutics USA in 2021. In 2022, Aleor Dermaceuticals was amalgamated into Alembic Pharmaceutical and became a wholly owned subsidiary.

Revenue: ₹1,692.74Cr as on December 2024 (Q4 24)
Net Profit: ₹137.70Cr as on December 2024 (Q4 24)
Listing date: 20 Sep, 2011
Chairperson Name: Chirayu R Amin
OrganisationAlembic Pharmaceuticals Ltd
HeadquartersVadodara
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Alembic Pharmaceuticals Ltd

What is Alembic Pharmaceuticals Ltd price today?

Alembic Pharmaceuticals Ltd share price today stands at ₹879.8, Open: ₹870.7, Previous Close: ₹870.7, High: ₹885.65, Low: ₹870.7, 52 Week High: ₹1303.9, 52 Week Low: ₹725.2.

How to Buy Alembic Pharmaceuticals Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Alembic Pharmaceuticals Ltd shares

What are today's traded volumes of Alembic Pharmaceuticals Ltd?

Today's traded volume of Alembic Pharmaceuticals Ltd(APLLTD) is 95.96K.

What is today's market capitalisation of Alembic Pharmaceuticals Ltd?

Today's market capitalisation of Alembic Pharmaceuticals Ltd(APLLTD) is ₹17114.75Cr.

What is the 52 Week High and Low Range of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd (APLLTD)
Price
52 Week High
₹1303.9
52 Week Low
₹725.2

How much percentage Alembic Pharmaceuticals Ltd is down from its 52 Week High?

Alembic Pharmaceuticals Ltd (APLLTD) share price is ₹879.8. It is down -32.53% from its 52 Week High price of ₹1303.9

How much percentage Alembic Pharmaceuticals Ltd is up from its 52 Week low?

Alembic Pharmaceuticals Ltd (APLLTD) share price is ₹879.8. It is up 21.32% from its 52 Week Low price of ₹725.2